Glen has made over 4 trades of the PhaseBio Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 11,248 units of PHAS stock worth $8,886 on 20 May 2022.
The largest trade he's ever made was selling 11,248 units of PhaseBio Pharmaceuticals stock on 20 May 2022 worth over $8,886. On average, Glen trades about 3,475 units every 78 days since 2020.
You can see the complete history of Mr. Burkhardt stock trades at the bottom of the page.
Glen G. Burkhardt serves as Vice President - Human Resources of the Company. Prior to joining our company, Mr. Burkhardt served as vice president of human resources for Hologic, Inc. from June 2014 to October 2018. He received a B.S. and a B.Arch. from Ball State University and an M.B.A. from the Kelley School of Business at Indiana University.
Glen Burkhardt is 61, he's been the Vice President - Human Resources of PhaseBio Pharmaceuticals since 2019. There are 3 older and 14 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.
Glen's mailing address filed with the SEC is C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN, PA, 19355.
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp..., eNancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include: